Jove
Visualize
联系我们

相关概念视频

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same journal

Combination antithrombotic therapy in atrial fibrillation after coronary interventions: shorter duration, more safety?

Lancet (London, England)·2026
Same journal

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026
Same journal

Bundibugyo ebolavirus from the 2026 Ebola outbreak in Uganda and DR Congo: a new variant.

Lancet (London, England)·2026
Same journal

Embracing neurodiversity in medicine: insights from the history of psychiatry.

Lancet (London, England)·2026
Same journal

Our commitment to early-career clinicians and academics.

Lancet (London, England)·2026
Same journal

Massive bilateral perirenal infiltration in Erdheim-Chester disease.

Lancet (London, England)·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jul 6, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

在已知HIV-1感染持续时间的人群中,引入HAART后的存活率. 这就是CASCADE协作. 关于欧洲艾滋病和死亡的血清转换的协调行动

    Lancet (London, England)
    |May 3, 2000
    PubMed
    概括

    随着高活性抗逆转录病毒疗法 (HAART) 的出现,HIV-1血清转化后的存活率显著改善. 在HAART时代 (1997-98) 诊断的个人与HAART前时期 (1986-96) 相比,显示出更好的生存预期.

    科学领域:

    • 免疫学 免疫学 免疫学
    • 病毒学 病毒学
    • 流行病学 流行病学

    背景情况:

    • 本研究评估了高活性抗逆转录病毒疗法 (HAART) 对人类免疫缺陷病毒1型 (HIV-1) 血清转换后的生存结果的影响.
    • 从前HAART时代 (1986-1996) 的生存数据与早期HAART时期 (1997-1998) 的生存数据进行比较.

    研究的目的:

    • 为了比较HIV-1感染者在HAART引入之前和之后的生存结果.
    • 量化HAART在HIV-1血清转化后对预期寿命的影响.

    主要方法:

    • 追溯队列分析,比较生存数据.
    • 分析了不同时期的HIV-1血清转化病例:HAART前 (1986-1996) 和HAART时代 (1997-1998).
    • 估计关键时间点的生存概率,包括血清转换后的10年.

    主要成果:

    • 在HIV-1血清转换后的生存预期在HAART期间 (1997-1998) 与HAART前时期 (1986-1996) 相比,在HAART期间 (1997-1998) 实质上更好.
    • 血清转换后10年的估计存活率在晚期的HAART时代队列中显著改善.
    • 在1997-1998年被诊断的个体表现出明显更好的生存轨迹比1986年至1996年间被诊断的个体.

    更多相关视频

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
    19:57

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

    Published on: March 30, 2014

    Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
    06:07

    Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

    Published on: October 6, 2022

    相关实验视频

    Last Updated: Jul 6, 2026

    Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
    23:56

    Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

    Published on: October 31, 2010

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
    19:57

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

    Published on: March 30, 2014

    Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
    06:07

    Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

    Published on: October 6, 2022

    结论:

    • 高活性抗逆转录病毒疗法 (HAART) 显著提高了HIV-1感染个体的存活率.
    • 过渡到HAART时代代表了管理HIV-1的重大进步,导致更好的长期患者结果.
    • 持续获得和遵守HAART对于最大限度地提高HIV-1阳性人群的预期寿命至关重要.